Does Semaglutide Come in Pill Form? Understanding Rybelsus, Compounded Oral Options, and What Actually Works

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Rybelsus is the only FDA-approved oral semaglutide, available in 3 mg, 7 mg, and 14 mg tablets for type 2 diabetes
• Oral semaglutide has roughly 1% bioavailability compared to 89% for subcutaneous injections, requiring co-formulation with SNAC absorption enhancer
• The 14 mg Rybelsus tablet delivers approximately the same systemic exposure as 0.5 mg injected semaglutide, not the 2.4 mg dose used for weight loss
• Compounded oral semaglutide formulations exist but face significant absorption barriers without proprietary enhancer technology

Direct answer (40-60 words)

Yes, semaglutide comes in pill form as Rybelsus, FDA-approved for type 2 diabetes in 3 mg, 7 mg, and 14 mg doses. However, oral semaglutide has approximately 1% bioavailability compared to 89% for injections. The highest Rybelsus dose (14 mg) delivers roughly the same blood levels as 0.5 mg injected semaglutide, far below the 2.4 mg weight-loss dose.

Table of contents

1. The FDA-approved oral option: what Rybelsus actually is
2. The absorption problem: why semaglutide doesn't survive the stomach
3. How SNAC technology solves the bioavailability barrier
4. Dose equivalency: what 14 mg oral really means
5. Clinical data: how oral performs vs injections for weight loss
6. The compounded oral semaglutide question
7. What most articles get wrong about oral semaglutide
8. The administration protocol: why timing matters for absorption
9. Who should consider oral semaglutide vs injections
10. The cost comparison: oral vs injectable
11. Future oral GLP-1 formulations in development
12. FAQ

The FDA-approved oral option: what Rybelsus actually is

Rybelsus is the brand name for oral semaglutide, approved by the FDA in September 2019 for type 2 diabetes management. It comes in three tablet strengths: 3 mg, 7 mg, and 14 mg. The medication contains the same active peptide as injectable Ozempic and Wegovy but uses a proprietary absorption technology called SNAC (salcaprozate sodium) to get the drug through the stomach intact.

The approval was based on the PIONEER trial program, which enrolled over 9,500 patients across 10 studies. Rybelsus demonstrated A1C reductions of 0.9% to 1.4% depending on dose, comparable to other oral diabetes medications but lower than injectable semaglutide's 1.5% to 2.0% reductions (Aroda et al., Lancet 2019).

Rybelsus is not FDA-approved for weight loss. The labeled indication is "adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus." Some providers prescribe it off-label for weight management, but insurance coverage for that indication is rare.

The tablet must be taken on an empty stomach with no more than 4 ounces of water, at least 30 minutes before any food, beverage, or other medication. This strict protocol is required for the absorption enhancer to work.

The absorption problem: why semaglutide doesn't survive the stomach

Semaglutide is a 31-amino-acid peptide with a molecular weight of 4,113 daltons. Peptides this large face three absorption barriers in the gastrointestinal tract:

1. Enzymatic degradation. Pepsin and other proteolytic enzymes in the stomach break peptide bonds, fragmenting semaglutide into inactive pieces before it reaches the small intestine where absorption occurs.

1. pH instability. Stomach acid (pH 1.5 to 3.5) denatures the peptide structure, destroying the specific folding required for GLP-1 receptor binding.

1. Poor membrane permeability. Even if semaglutide survived the stomach intact, its large molecular weight and hydrophilic character prevent passive diffusion across the intestinal epithelium. Molecules above 500 daltons rarely cross the gut barrier without active transport.

Early oral semaglutide formulations without absorption enhancers showed bioavailability below 0.4%, meaning less than 1 out of every 200 mg swallowed reached systemic circulation (Buckley et al., Diabetes Obesity and Metabolism 2018). This made oral delivery commercially nonviable.

The problem isn't unique to semaglutide. Insulin, exenatide, liraglutide, and other peptide drugs all require injection for the same reasons. The GI tract evolved to break down dietary proteins, not preserve therapeutic ones.

How SNAC technology solves the bioavailability barrier

SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) is a small-molecule absorption enhancer co-formulated with semaglutide in Rybelsus tablets. It works through three mechanisms:

1. Local pH buffering. SNAC raises the pH in the immediate microenvironment around the dissolving tablet from approximately 2.0 to 5.0, reducing acid-catalyzed peptide degradation.

1. Transient membrane permeabilization. SNAC reversibly opens tight junctions between epithelial cells in the gastric mucosa, creating paracellular transport pathways large enough for semaglutide to pass through.

1. Protease inhibition. SNAC temporarily reduces pepsin activity in the local area, giving semaglutide a window to cross the membrane before enzymatic breakdown occurs.

The effect is transient and localized. SNAC doesn't systemically alter stomach pH or permanently damage the gastric lining. Within 60 to 90 minutes after tablet dissolution, tight junctions close and normal protease activity resumes (Buckley et al., Journal of Pharmacology and Experimental Therapeutics 2018).

The technology increases semaglutide bioavailability from less than 0.4% to approximately 0.4% to 1.0% depending on dose and individual gastric physiology. That 1% figure is the key constraint: you need 100 times more oral semaglutide than injected semaglutide to achieve equivalent blood levels.

SNAC is proprietary to Novo Nordisk. Generic or compounded oral semaglutide formulations cannot legally use SNAC, which is why absorption remains a barrier for non-branded oral products.

Dose equivalency: what 14 mg oral really means

The dose numbers on Rybelsus tablets are misleading without context. A 14 mg Rybelsus tablet does not deliver 14 mg of semaglutide to your bloodstream. It delivers approximately 0.14 mg (140 micrograms) after accounting for 1% bioavailability.

Pharmacokinetic modeling from the PIONEER trials shows:

Oral dose (Rybelsus)	Approximate injectable equivalent	Typical use case
3 mg daily	~0.03 mg weekly	Titration starter dose
7 mg daily	~0.07 mg weekly	Low-end maintenance for diabetes
14 mg daily	~0.5 mg weekly	Maximum approved oral dose

For comparison, injectable semaglutide dosing:

• Ozempic for diabetes: 0.5 mg or 1 mg weekly
• Wegovy for weight loss: 2.4 mg weekly (titrated up from 0.25 mg)

The 14 mg Rybelsus dose delivers systemic exposure roughly equivalent to 0.5 mg Ozempic, which is the lower of the two diabetes maintenance doses. It's nowhere near the 2.4 mg dose used for weight loss in the STEP trials.

This explains why Rybelsus is approved only for diabetes, not obesity. The absorption barrier prevents achieving weight-loss-effective blood levels without swallowing tablets so large they become impractical.

A hypothetical oral formulation equivalent to 2.4 mg injected semaglutide would require approximately 67 mg of oral semaglutide daily, assuming 1% bioavailability and linear dose-response. No such product exists.

Clinical data: how oral performs vs injections for weight loss

Rybelsus was never studied at doses designed to match injectable semaglutide for weight loss, but the PIONEER 4 trial (Pratley et al., Lancet 2019) compared 14 mg oral semaglutide to 1 mg injectable semaglutide in 711 patients with type 2 diabetes over 52 weeks.

Weight loss results:

• 14 mg oral semaglutide: 4.4 kg (9.7 lbs) average loss
• 1 mg injectable semaglutide: 6.5 kg (14.3 lbs) average loss
• Placebo: 0.5 kg (1.1 lbs) average loss

The injectable form produced 48% more weight loss than the oral form despite both being approved diabetes doses. The gap widens further when comparing oral semaglutide to the 2.4 mg weight-loss dose.

The STEP 1 trial (Wilding et al., New England Journal of Medicine 2021) showed 2.4 mg injectable semaglutide produced 14.9% total body weight loss over 68 weeks. No published trial of oral semaglutide has approached that magnitude.

A1C reduction showed a similar pattern in PIONEER 4:

• 14 mg oral: 1.2% A1C reduction
• 1 mg injectable: 1.4% A1C reduction

The oral form works. It's a legitimate GLP-1 agonist with proven glycemic and weight benefits. But the absorption barrier means it can't match injectable dosing for magnitude of effect.

The compounded oral semaglutide question

Some compounding pharmacies advertise oral semaglutide formulations, typically as sublingual tablets, troches, or rapid-dissolve films. These products face the same absorption barriers as any oral peptide without SNAC technology.

The sublingual route (under the tongue, absorbed through oral mucosa) theoretically bypasses the stomach, but semaglutide's molecular weight and hydrophilicity still prevent efficient absorption. Published data on sublingual semaglutide bioavailability is sparse, but small studies suggest absorption rates between 2% and 5%, modestly better than swallowed tablets but far below injections (Lau et al., Pharmaceutical Research 2015).

Compounded oral semaglutide formulations cannot legally use SNAC, which is protected by Novo Nordisk patents. Without an absorption enhancer, the dose required to match injectable efficacy becomes impractically large and expensive.

The FDA has not approved any compounded oral semaglutide product. Compounded medications are prepared in response to individual prescriptions and do not undergo the same safety and efficacy review as FDA-approved drugs.

Patients considering compounded oral semaglutide should ask their provider and pharmacy:

• What is the expected bioavailability of this formulation?
• What absorption-enhancing technology is used, if any?
• What published evidence supports the dosing protocol?
• How does the cost per unit of absorbed semaglutide compare to injections?

In most cases, the cost-benefit calculation favors injections. A 14 mg Rybelsus tablet costs approximately $900 per month without insurance. Compounded injectable semaglutide typically costs $200 to $400 per month for doses that deliver far higher systemic exposure.

What most articles get wrong about oral semaglutide

The most common error in published content on this topic is treating "oral semaglutide" and "injectable semaglutide" as interchangeable options that differ only in delivery method, like choosing between tablet ibuprofen and liquid ibuprofen.

The reality: oral and injectable semaglutide are not dose-equivalent alternatives. They're different pharmacokinetic products that happen to contain the same active peptide.

Specific misconceptions:

Misconception 1: "Rybelsus goes up to 14 mg, so it's a higher dose than 2.4 mg Wegovy."

Wrong. The 14 mg refers to the amount of semaglutide in the tablet, not the amount absorbed. After accounting for 1% bioavailability, 14 mg oral delivers roughly the same systemic exposure as 0.5 mg injected. The numbers aren't comparable.

Misconception 2: "Oral semaglutide is just as effective as injections for weight loss."

Wrong. No head-to-head trial has compared oral semaglutide to 2.4 mg injectable semaglutide for weight loss. The PIONEER 4 trial showed 14 mg oral produced 48% less weight loss than 1 mg injectable. Extrapolating to 2.4 mg injectable, the gap would be even larger.

Misconception 3: "You can avoid injections by switching to Rybelsus."

Technically true, but misleading. If you're on 2.4 mg Wegovy and switch to 14 mg Rybelsus, you'll lose most of the weight-loss effect because the systemic exposure drops by approximately 80%. You're not switching to an equivalent oral form. You're switching to a much lower effective dose.

Misconception 4: "Compounded oral semaglutide works just as well as Rybelsus."

Unlikely without SNAC or equivalent absorption technology. Compounded sublingual formulations may achieve 2% to 5% bioavailability vs Rybelsus's 1%, but that's still 95% to 98% waste. The dose required to match injections becomes prohibitively expensive.

The corrected framing: oral semaglutide is a legitimate option for patients who absolutely cannot or will not inject and are willing to accept lower efficacy. It's not a same-efficacy alternative delivery method.

The administration protocol: why timing matters for absorption

Rybelsus has the most restrictive administration requirements of any oral diabetes medication. The protocol is non-negotiable for absorption:

Step 1: Take on completely empty stomach.

• First thing in the morning, before any food or drink except water
• At least 8 hours after your last meal (overnight fast satisfies this)
• If you wake up and drink coffee, eat breakfast, or take other medications first, Rybelsus absorption drops by 50% or more

Step 2: Use minimal water.

• No more than 4 ounces (half a cup)
• Swallow the tablet whole (do not crush, chew, or split)
• The small water volume is required for SNAC to create the right local pH environment

Step 3: Wait 30 minutes before anything else.

• No food, no beverages (including coffee, tea, or additional water), no other medications
• Waiting less than 30 minutes reduces absorption by up to 50%
• Waiting 60 minutes is better than 30 if your schedule allows

The 30-minute wait is the most common adherence failure point. Patients who take Rybelsus and then eat breakfast 15 minutes later because they're hungry are getting a fraction of the intended dose.

Why the strict protocol? SNAC needs time to buffer the local pH, open tight junctions, and allow semaglutide to cross the gastric mucosa before food arrives and triggers normal digestive processes. Food in the stomach dilutes SNAC, lowers its local concentration, and activates proteases that degrade semaglutide.

The protocol is easier to follow than it sounds for most patients. Set an alarm 30 minutes before your normal breakfast time, take the tablet with a small glass of water, then go about your morning routine. By the time you're ready to eat, the 30-minute window has passed.

Missing the protocol occasionally (once or twice per month) probably doesn't matter much. Missing it consistently (taking Rybelsus with breakfast every day) turns it into an expensive placebo.

Who should consider oral semaglutide vs injections

Oral semaglutide makes sense for a specific patient profile. The decision tree:

Consider oral semaglutide (Rybelsus) if:

• You have needle phobia severe enough that you'd rather accept lower efficacy than inject
• You have type 2 diabetes and need modest A1C reduction (0.9% to 1.4%) plus modest weight loss (4 to 5 kg)
• You can reliably follow the 30-minute fasting protocol every morning
• Insurance covers Rybelsus (many plans do for diabetes, almost none for weight loss)
• You've tried other oral diabetes medications and need to add a GLP-1 agonist

Choose injectable semaglutide if:

• Your primary goal is weight loss (2.4 mg injectable is far more effective)
• You want maximum A1C reduction for diabetes (1.5% to 2.0% with injectables)
• You can't consistently follow the Rybelsus morning protocol
• You're paying out of pocket (compounded injectable is usually cheaper per unit of efficacy)
• You're already comfortable with injections or willing to learn

The needle-phobia calculation:

Modern semaglutide injection pens use 32-gauge needles (0.23 mm diameter), thinner than most acupuncture needles. The injection is subcutaneous (into fat, not muscle), takes 5 seconds, and most patients report it's less painful than a finger-prick glucose test.

If needle phobia is the only barrier, exposure therapy with supervised first injection often resolves it. Many patients who thought they "could never inject" find the reality far less distressing than the anticipation.

If needle phobia persists despite exposure, oral semaglutide is a reasonable compromise. But framing it as "I'm choosing the oral version because it's just as good" sets up disappointment when results don't match injectable outcomes.

FormBlends clinical pattern:

Across patient inquiries about oral vs injectable options, the most common decision pattern we see is: initial preference for oral based on injection avoidance, followed by switch to injectable after 8 to 12 weeks when weight loss plateaus below expectations. Patients who start with injections rarely request a switch to oral. The efficacy difference becomes apparent quickly enough that most patients conclude the injection is worth it.

The patients who stay on oral long-term tend to be those using it for diabetes management rather than weight loss, where the lower systemic exposure still provides meaningful glycemic benefit.

The cost comparison: oral vs injectable

Retail pricing without insurance (April 2026):

Product	Dose	Monthly cost	Cost per 1% body weight lost*
Rybelsus 14 mg	30 tablets	$935	$254
Ozempic 1 mg	4 weekly injections	$968	$161
Wegovy 2.4 mg	4 weekly injections	$1,349	$90
Compounded semaglutide 2.4 mg	4 weekly injections	$300-$450	$30-$45

*Estimated based on average weight loss in published trials: Rybelsus 3.7%, Ozempic 1 mg 6%, Wegovy 15%, compounded assumed equivalent to Wegovy.

The cost-per-outcome calculation favors injectable semaglutide by a wide margin. Rybelsus costs roughly the same per month as brand-name Ozempic but delivers less than half the weight loss.

Insurance coverage patterns:

• Rybelsus: covered by most plans for type 2 diabetes with prior authorization, rarely covered for weight loss
• Ozempic: covered for diabetes, sometimes covered off-label for weight loss
• Wegovy: covered by approximately 40% of commercial plans for obesity with BMI criteria
• Compounded semaglutide: not covered by insurance (cash pay only)

For patients paying out of pocket, compounded injectable semaglutide costs one-third as much as Rybelsus and delivers roughly four times the weight loss. The math is unambiguous.

For patients with insurance coverage, the calculation depends on copay structure. If your plan covers Rybelsus with a $30 copay but doesn't cover Wegovy, Rybelsus becomes the affordable option despite lower efficacy.

Future oral GLP-1 formulations in development

Several pharmaceutical companies are developing next-generation oral GLP-1 agonists designed to overcome the absorption barrier without SNAC:

Orforglipron (Eli Lilly): A small-molecule GLP-1 receptor agonist (not a peptide) with 90% oral bioavailability. Phase 3 trials showed 14.7% weight loss at 45 mg daily dose, comparable to injectable tirzepatide (Jastreboff et al., New England Journal of Medicine 2023). Expected FDA submission late 2026.

Danuglipron (Pfizer): Another small-molecule GLP-1 agonist. Phase 2 data showed 6.9% weight loss at 200 mg twice daily. Development paused in 2023 due to high discontinuation rates from nausea and vomiting, but Pfizer is reformulating for once-daily dosing.

Oral tirzepatide (Eli Lilly): An oral version of the dual GLP-1/GIP agonist currently marketed as Mounjaro and Zepbound. Uses a different absorption enhancer than SNAC. Phase 1 trials completed, Phase 2 expected 2026.

The key innovation in these pipeline products is switching from peptides (which require absorption enhancers) to small molecules (which don't). Orforglipron and danuglipron are true oral alternatives with bioavailability comparable to injections.

If orforglipron gains FDA approval in 2027 as expected, it will be the first oral GLP-1 medication that doesn't sacrifice efficacy for convenience. Until then, Rybelsus remains the only option, with its inherent absorption limitations.

FAQ

Does semaglutide come in pill form? Yes, Rybelsus is FDA-approved oral semaglutide available in 3 mg, 7 mg, and 14 mg tablets for type 2 diabetes. However, oral bioavailability is approximately 1% compared to 89% for injections, so the highest oral dose (14 mg) delivers roughly the same blood levels as 0.5 mg injected semaglutide.

Is Rybelsus the same as Ozempic? Both contain semaglutide, but Rybelsus is oral and Ozempic is injectable. Due to absorption differences, 14 mg Rybelsus delivers approximately the same systemic exposure as 0.5 mg Ozempic. They're not dose-equivalent alternatives.

Can I take Rybelsus instead of Wegovy for weight loss? Rybelsus is not FDA-approved for weight loss and delivers far lower systemic semaglutide exposure than Wegovy. The 14 mg Rybelsus dose is roughly equivalent to 0.5 mg injected semaglutide, while Wegovy uses 2.4 mg. Weight loss with Rybelsus averages 4 to 5 kg vs 15 kg with Wegovy.

Why is oral semaglutide less effective than injections? Semaglutide is a large peptide that gets broken down by stomach acid and digestive enzymes. Even with SNAC absorption enhancer technology, only about 1% of an oral dose reaches the bloodstream compared to 89% of an injected dose.

How much does Rybelsus cost? Approximately $935 per month for 30 tablets of the 14 mg dose without insurance. Many insurance plans cover it for type 2 diabetes with prior authorization. Coverage for weight loss is rare.

Can compounding pharmacies make oral semaglutide? Some compounding pharmacies offer sublingual or oral semaglutide formulations, but these cannot legally use SNAC technology (proprietary to Novo Nordisk). Without an absorption enhancer, bioavailability remains very low, typically 2% to 5% at best.

Do I have to take Rybelsus on an empty stomach? Yes. Rybelsus must be taken first thing in the morning with no more than 4 ounces of water, at least 30 minutes before any food, beverage, or other medication. Taking it with food reduces absorption by 50% or more.

What happens if I eat breakfast right after taking Rybelsus? Absorption drops significantly. The SNAC absorption enhancer needs 30 minutes to work before food enters the stomach. Eating sooner means you're getting a fraction of the intended dose.

Is oral semaglutide safer than injections? The side effect profile is similar: nausea, diarrhea, constipation, and abdominal pain are common with both forms. Oral semaglutide has slightly higher rates of nausea during titration. Serious risks (pancreatitis, gallbladder disease, thyroid tumors in animal studies) are the same.

Can I switch from injectable to oral semaglutide? You can, but expect reduced efficacy. If you're on 2.4 mg Wegovy and switch to 14 mg Rybelsus, your systemic semaglutide exposure drops by approximately 80%. Most patients who switch experience weight regain and worsening glycemic control.

Will insurance cover Rybelsus for weight loss? Rarely. Rybelsus is FDA-approved only for type 2 diabetes. Some providers prescribe it off-label for weight management, but most insurance plans deny coverage for non-approved indications. Coverage for diabetes is common with prior authorization.

Is there a generic version of Rybelsus? Not yet. Rybelsus is protected by patents through 2032. Generic oral semaglutide cannot legally use SNAC technology, which means generic versions would have even lower bioavailability than branded Rybelsus.

How long does it take for Rybelsus to work? A1C reduction becomes measurable within 4 to 8 weeks. Weight loss typically begins within 2 to 4 weeks and continues for 6 to 12 months. Maximum effect occurs around 52 weeks of treatment.

Can I take Rybelsus if I'm afraid of needles? Yes, that's the primary use case for choosing oral over injectable semaglutide. However, you should understand that efficacy is significantly lower. If needle phobia is the only barrier, consider working with your provider on exposure therapy, as modern injection pens use very thin needles and most patients find the process far less distressing than anticipated.

What's the difference between Rybelsus and metformin? Both are oral medications for type 2 diabetes, but they work through different mechanisms. Metformin reduces glucose production in the liver and improves insulin sensitivity. Rybelsus is a GLP-1 agonist that increases insulin secretion and slows gastric emptying. Rybelsus typically produces more weight loss (4 to 5 kg vs 2 to 3 kg for metformin).

Sources

1. Aroda VR et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019.
2. Pratley R et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018.
5. Buckley ST et al. The Dynamics of Small Intestinal Absorption of a Small Molecule and a Macromolecule. Journal of Pharmacology and Experimental Therapeutics. 2018.
6. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
7. Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. New England Journal of Medicine. 2023.
8. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
9. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015.
10. Husain M et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2019.
11. Rodbard HW et al. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes Care. 2019.
12. Zinman B et al. Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. Diabetes Care. 2019.
13. Pieber TR et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinology. 2019.
14. Mosenzon O et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinology. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Rybelsus, Ozempic, and Wegovy are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.